Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of anisodine hydrobromide in treatment of Parkinson's disease

A technology of anisodine hydrobromide and hydrobromic acid, applied in the field of anisodine hydrobromide in the treatment of Parkinson's disease, to achieve the effect of improving motor function, improving quality of life, and preventing complications

Pending Publication Date: 2022-07-15
CHENGDU FIRST PHARMACEDTICAL CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to solve the technical problems in the above-mentioned background technology that can be superior to the existing conventional treatment methods based on drug treatments such as levodopa and dopamine, the present invention provides a kind of anisodine hydrobromide used in the treatment of Parkinson's disease the use of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of anisodine hydrobromide in treatment of Parkinson's disease
  • Application of anisodine hydrobromide in treatment of Parkinson's disease
  • Application of anisodine hydrobromide in treatment of Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1. Clinical efficacy observation of anisodine hydrobromide tablets in the treatment of Parkinson's disease

[0032] 1.1. Experiment preparation

[0033] A prospective randomized controlled clinical trial method was used to select 300 patients who were diagnosed with Parkinson's disease in the research unit from March 2020 to March 2021, and who met the diagnostic criteria for Parkinson's disease in China (2016 version) and inclusion and exclusion criteria. , including 163 males and 137 females. According to the random number table, they were randomly divided into the experimental group and the control group, with 150 cases in each group. The mean age of the patients in the experimental group was 58.79±3.31 years, and the mean disease duration was 3.46±1.75 years; the mean age of the patients in the control group was 59.45±3.02 years, and the mean disease duration was 3.38±1.64 years. There was no significant difference in age and course of disease between t...

Embodiment 2

[0083] Embodiment 2. Clinical observation of the clinical efficacy of anisodine hydrobromide injection in the treatment of acute tremor in Parkinson's disease

[0084] 1.1. Experiment preparation

[0085] In this experiment, a prospective randomized controlled clinical trial method was used to select patients diagnosed with acute tremor of Parkinson's disease in the research unit from July 2020 to November 2021, who met the diagnostic criteria for Parkinson's disease in China (2016 version) and inclusion and exclusion criteria 280 patients, including 150 males and 130 females. According to the random number table, they were randomly divided into the experimental group and the control group, with 140 cases in each group. The mean age of the patients in the experimental group was 62.23±2.31 years, and the mean disease duration was 3.82±1.67 years; the mean age of the patients in the control group was 62.16±2.07 years, and the mean disease duration was 3.61±1.78 years. There wa...

Embodiment 3

[0122] Embodiment 3. Observation on the clinical efficacy of sequential treatment of Parkinson's disease with Anisodine Hydrobromide Injection and Anisodine Hydrobromide Tablets

[0123] 1.1. Experiment preparation

[0124] In this experiment, a prospective randomized controlled clinical trial method was used to select patients diagnosed with Parkinson's disease in the research unit from December 2020 to December 2021, who met the diagnostic criteria for Parkinson's disease in China (2016 version) and the inclusion and exclusion criteria. 350 cases, including 195 males and 155 females. According to the random number table, they were randomly divided into the experimental group and the control group, with 175 cases in each group. The mean age of the patients in the experimental group was 58.43±3.48 years, and the mean disease duration was 3.37±1.72 years; the mean age of the patients in the control group was 58.24±3.14 years, and the mean disease duration was 3.52±1.61 years. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of new application of medicines, in particular to application of anisodine hydrobromide in treatment of Parkinson's disease. The Parkinson's disease (PD) is a common neurodegenerative disease, the motion symptoms of the PD are acute or static tremor, motion retardation, myotonia, posture balance disorder and the like, at present, the Parkinson's disease is clinically treated mainly by drugs such as levodopa and dopamine, but drug resistance appears along with the prolonging of medication time, and the Parkinson's disease is caused by the drug resistance. The treatment effect and rehabilitation are directly influenced. The anisodine hydrobromide can well improve the treatment effect and shorten the treatment time, so that the influence of drug resistance is reduced.

Description

technical field [0001] The invention belongs to the field of new uses of medicines, in particular to the use of anisodine hydrobromide in the treatment of Parkinson's disease. Background technique [0002] Parkinson's disease (PD) is a common neurodegenerative disease with motor symptoms such as acute or resting tremor, bradykinesia, muscle rigidity, and postural balance disorders. Depression-like symptoms such as fatigue, constipation, and lethargy. Epidemiological surveys show that the number of PD patients in the world has reached 6 million, and the proportion of people over 60 years old with the disease is about 1%. It is estimated that by 2030, the number of PD patients in my country may reach 5 million. Anisodine hydrobromide is an M choline receptor antagonist, mainly used in vascular headache, retinal vasospasm, ischemic optic neuropathy, acute paralysis, tremor paralysis, etc. It can also be used in the detoxification of organophosphorus pesticide poisoning. [0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/439A61K9/08A61K9/20A61P25/16
CPCA61K31/439A61K9/08A61K9/0019A61K9/20A61P25/16
Inventor 万峰成云芳王燚冷为军王恒黎欣肖芳宋艳艳
Owner CHENGDU FIRST PHARMACEDTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com